Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rina-S vs Investigator's Choice in Endometrial Cancer
NCT07166094Phase 3Recruiting
- Sponsor
- Genmab
- Start
- Nov 2025
- Primary completion
- Aug 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of rinatabart sesutecan in endometrial cancer (EC), sponsored by Genmab. Started Nov 2025; status: recruiting.
02
Drugs
rinatabart sesutecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07166094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07166094.